NO331183B1 - Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer - Google Patents

Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer

Info

Publication number
NO331183B1
NO331183B1 NO20093217A NO20093217A NO331183B1 NO 331183 B1 NO331183 B1 NO 331183B1 NO 20093217 A NO20093217 A NO 20093217A NO 20093217 A NO20093217 A NO 20093217A NO 331183 B1 NO331183 B1 NO 331183B1
Authority
NO
Norway
Prior art keywords
halochondrine
analogue
pharmaceutical
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
NO20093217A
Other languages
English (en)
Other versions
NO20093217L (no
Inventor
Wanjun Zheng
Bruce A Littlefield
Boris M Seletsky
Murray J Towle
Melvin J Yu
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331183(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20093217L publication Critical patent/NO20093217L/no
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO331183B1 publication Critical patent/NO331183B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det er beskrevet halikondrinanaloger som har farmasøytisk aktivitet, så som anti-kreft eller anti-mitotisk (mitoseblokkerende) aktivitet, og fremgangsmåter for å identifisere midler som induserer en vedvarende mitotisk blokkering i en celle etter transient eksponering av cellen mot midlene.
NO20093217A 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer NO331183B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17

Publications (2)

Publication Number Publication Date
NO20093217L NO20093217L (no) 2001-02-15
NO331183B1 true NO331183B1 (no) 2011-10-24

Family

ID=22219026

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger
NO20093217A NO331183B1 (no) 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no) 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no) 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Country Status (23)

Country Link
US (4) US6214865B1 (no)
EP (4) EP2277873B1 (no)
JP (1) JP4454151B2 (no)
KR (1) KR100798600B1 (no)
CN (1) CN1216051C (no)
AT (1) ATE502932T1 (no)
AU (1) AU762998B2 (no)
BE (1) BE2011C028I2 (no)
BR (1) BRPI9911326B8 (no)
CA (3) CA2632433C (no)
CY (2) CY1111516T1 (no)
DE (2) DE69943296D1 (no)
DK (1) DK1087960T3 (no)
FR (1) FR11C0038I2 (no)
HK (1) HK1035534A1 (no)
HU (1) HU227912B1 (no)
IL (1) IL139960A0 (no)
LU (1) LU91854I2 (no)
NO (5) NO328280B1 (no)
NZ (1) NZ508597A (no)
PT (1) PT1087960E (no)
WO (1) WO1999065894A1 (no)
ZA (1) ZA200007159B (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6214865B1 (en) 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
PL219737B1 (pl) 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
WO2004105794A2 (en) * 2003-05-29 2004-12-09 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005011589A2 (en) * 2003-07-29 2005-02-10 Eisai Co., Ltd. Drug delivery methods and devices
CN109180615A (zh) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
EP2949652B1 (en) 2004-06-03 2019-08-07 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
CN105801599A (zh) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
MX2011009632A (es) 2009-03-30 2011-10-19 Eisai R&D Man Co Ltd Composicion de liposoma.
EP2420504B1 (en) * 2009-04-14 2014-01-15 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
US8203010B2 (en) * 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
ES2731653T3 (es) 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Métodos y usos para predecir la respuesta a la eribulina
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN104053645A (zh) 2011-11-30 2014-09-17 阿方拉研究股份有限公司 用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
WO2013097042A1 (en) * 2011-12-29 2013-07-04 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
IN2014MN02106A (no) * 2012-03-30 2015-09-11 Alphora Res Inc
KR20150090921A (ko) 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도
AU2014268086A1 (en) 2013-05-15 2015-11-05 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
RU2672585C2 (ru) 2013-06-26 2018-11-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
JP6511613B2 (ja) * 2013-07-03 2019-05-15 サンド・アクチエンゲゼルシヤフト ハリコンドリンＢの大環状Ｃ１−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−ＳＯ２−（ｐ−トリル）基を含有する中間体
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
EP3066102B1 (en) 2013-11-04 2020-02-26 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
WO2015183961A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
EP3160970A4 (en) * 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
EP3265122B1 (en) * 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN117024469A (zh) 2015-05-07 2023-11-10 卫材R&D管理有限公司 可用于合成软海绵素大环内酯的大环化反应以及中间体和其他片段
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX2018009794A (es) 2016-02-12 2018-12-17 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR20190009326A (ko) * 2016-05-26 2019-01-28 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그의 중간체의 제조방법
CN109641917B (zh) 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
MX2019003994A (es) 2016-10-14 2019-09-19 Merck Sharp & Dohme Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
KR20190084065A (ko) 2016-11-23 2019-07-15 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그 중간체의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN110139866B (zh) * 2017-01-02 2022-05-17 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体以及制备其的方法
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
IL288991B2 (en) 2017-04-05 2023-12-01 Harvard College A macrocyclic compound and its uses
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SG11201912342QA (en) 2017-07-06 2020-01-30 Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
US11142509B2 (en) 2017-11-09 2021-10-12 Yonsung Fine Chemical Co., Ltd. Intermediate for preparing eribulin mesylate and process for preparing the same
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
WO2019136145A1 (en) 2018-01-03 2019-07-11 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
JP2021532102A (ja) * 2018-07-20 2021-11-25 ドクター レディズ ラボラトリーズ リミテッド エリブリンおよびその中間体の調製のための精製プロセス
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
CA3168654A1 (en) * 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
TW202310878A (zh) * 2021-07-22 2023-03-16 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US6214865B1 (en) * 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
EP2949652B1 (en) 2004-06-03 2019-08-07 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
EP2200992B1 (en) * 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
US20090203771A1 (en) * 2007-11-16 2009-08-13 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CN105801599A (zh) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
US8203010B2 (en) * 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs

Also Published As

Publication number Publication date
DE122011100031I1 (de) 2011-12-15
BR9911326B1 (pt) 2015-01-06
FR11C0038I2 (fr) 2013-01-11
BRPI9911326B8 (pt) 2021-05-25
CN1312804A (zh) 2001-09-12
EP1087960A1 (en) 2001-04-04
EP1087960A4 (en) 2004-12-01
CA2755266C (en) 2014-08-12
US6469182B1 (en) 2002-10-22
PT1087960E (pt) 2011-06-17
CA2335300A1 (en) 1999-12-23
AU762998B2 (en) 2003-07-10
NO2011026I2 (no) 2012-06-11
US20110172446A1 (en) 2011-07-14
CA2755266A1 (en) 1999-12-23
CY1111516T1 (el) 2014-04-09
CA2632433C (en) 2012-02-07
AU4573999A (en) 2000-01-05
CA2632433A1 (en) 1999-12-23
ZA200007159B (en) 2001-12-04
EP2277873B1 (en) 2012-05-30
WO1999065894A1 (en) 1999-12-23
EP2272839B1 (en) 2012-08-22
CY2011010I2 (el) 2014-04-09
NO20006316D0 (no) 2000-12-12
FR11C0038I1 (fr) 2011-10-14
EP1087960B1 (en) 2011-03-23
US6214865B1 (en) 2001-04-10
NO2011026I1 (no) 2012-01-09
EP2272840A1 (en) 2011-01-12
ATE502932T1 (de) 2011-04-15
JP2002518384A (ja) 2002-06-25
NO2022019I1 (no) 2022-06-03
DK1087960T3 (da) 2011-06-14
US6365759B1 (en) 2002-04-02
HU227912B1 (en) 2012-05-29
KR20010083050A (ko) 2001-08-31
HUP0103357A2 (hu) 2002-01-28
JP4454151B2 (ja) 2010-04-21
HK1035534A1 (en) 2001-11-30
EP2272840B1 (en) 2012-08-22
NO20006316L (no) 2001-02-15
CA2335300C (en) 2008-10-07
CN1216051C (zh) 2005-08-24
DE69943296D1 (de) 2011-05-05
EP2277873A1 (en) 2011-01-26
KR100798600B1 (ko) 2008-01-28
NO2011018I1 (no) 2011-09-26
BR9911326A (pt) 2001-04-03
IL139960A0 (en) 2002-02-10
NZ508597A (en) 2004-01-30
AU762998C (en) 2000-01-05
BE2011C028I2 (en) 2018-08-24
EP2272839A1 (en) 2011-01-12
CY2011010I1 (el) 2014-04-09
NO20093217L (no) 2001-02-15
LU91854I2 (fr) 2011-10-17
HUP0103357A3 (en) 2002-10-28
NO328280B1 (no) 2010-01-25
US8148554B2 (en) 2012-04-03
RU2245335C2 (ru) 2005-01-27

Similar Documents

Publication Publication Date Title
NO331183B1 (no) Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
ES2167116T3 (es) Sistema terapeutico transdermico (tts) que contiene pergolida.
TR200002191T2 (tr) Potasyum kanal önleyicileri
BR0110079A (pt) Combinação de compostos orgânicos
BR0011597A (pt) Método para separar compostos orgânicos análogos e resina de troca iÈnica
BRPI0518580A2 (pt) mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
WO2004050033A3 (en) Method of treating cancers
AR024138A1 (es) Inhibidores de la proliferacion celular
DK1297013T3 (da) Anvendelse af TACI som antitumormiddel
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
BRPI0309651B8 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
HRP20010256B1 (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DK0790246T3 (da) Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
BR9908910A (pt) Sistema terapêutico transdérmico (tts) para a administração transcutânea de oxibutinina e método para sua preparação
NO20012817L (no) Fenetyl-5-brompyridyltiourea (PBT) og dihydroalkoksybenzyloksopyrimidin (DABO) derivater som utoverspermicidal aktivitet
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
Fleuranceau-Morel et al. Origin of 4-hydroxynonenal incubation-induced inhibition of dopamine transporter and Na+/K+ adenosine triphosphate in rat striatal synaptosomes
Rustenbeck et al. Polyamine modulation of mitochondrial calcium transport: II. Inhibition of mitochondrial permeability transition by aliphatic polyamines but not by aminoglucosides
IT1229563B (it) Composti tipo sali, composizioni farmaceutiche che li contengono e procedimento per la loro preparazione.
IT1283110B1 (it) Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2011026

Filing date: 20111214

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2011026

Filing date: 20111214

Extension date: 20240616

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2022019

Filing date: 20220603

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; REG. NO/DATE: EU/1/11/678 20220603

Spc suppl protection certif: 2022025

Filing date: 20220613

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2022019

Filing date: 20220603

Extension date: 20241216